Updates on AHPA activities and resources delivered to your inbox. Subscribe today!
The U.S. Food and Drug Administration (FDA) convened a teleconference meeting on March 18 (FDA Briefing for Foods Stakeholders on Coronavirus Disease 2019 (COVID-19)), which was attended by AHPA president Michael McGuffin and by representatives of AHPA’s general counsel, Kleinfeld, Kaplan & Becker, LLP.
As we all try to adapt to rapid changes, please note that the services AHPA provides and the commitment we share with you to our mission to support responsible commerce in herbal products will not change. We are taking precautions in response to this current emergency, so AHPA’s staff are now all working remotely. Each of us can be reached at our normal phone numbers and email addresses (see here).
Due to overwhelming demand, AHPA is presenting a second, expanded Hemp-CBD Supplement Congress in Portland, OR to provide companies with an understanding of federal and state legal and regulatory obligations and current issues and opportunities in the hemp-CBD market.
AHPA has compiled answers to frequently asked questions and resources to help prepare for and respond to COVID-19. This page will be revised and updated regularly as new information about the novel coronavirus (SARS-CoV-2) and possible impacts on the herbal products industry and the people who work in this trade becomes available.
The March 2020 AHPA Report includes a discussion of proposals to make supplement regulation more efficient and effective, the Cannabis Committee's 10-year anniversary, AERs and supplement safety, postponed events and an update on international supplement regulation from IADSA.